Clene Inc CLNN Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$3.10 down $0.21, 6.20% at close Oct 16
Last close · Previous close $3.31
- Market cap
- At the Oct 16 close
- P/E ratio
- On last 12 months’ EPS
- Diluted EPS
- Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$3.10down $0.21, 6.20%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$3.31Oct 15
- Volume204.44KOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume103.11KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $3.02 to $13.50; now $3.10
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
CLNN trailed the S&P 500 in all 6 periods.
| Period | CLNN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CLNN: down 19.7% S&P 500: up 1.5% | CLNN trailed the S&P 500 by 21.2 percentage points Trailed |
| 3M | CLNN: down 45.5% S&P 500: up 1.9% | CLNN trailed the S&P 500 by 47.4 percentage points Trailed |
| YTD | CLNN: down 47.2% S&P 500: up 12.8% | CLNN trailed the S&P 500 by 60.0 percentage points Trailed |
| 1Y | CLNN: down 62.4% S&P 500: up 16.8% | CLNN trailed the S&P 500 by 79.2 percentage points Trailed |
| Long term | ||
| 3Y | CLNN: down 70.2% S&P 500: up 81.5% −33.2% vs +22.0% a year | CLNN trailed the S&P 500 by 151.7 percentage points Trailed |
| 5Y | CLNN: down 97.5% S&P 500: up 83.1% −52.1% vs +12.9% a year | CLNN trailed the S&P 500 by 180.6 percentage points Trailed |
$10,000 invested in CLNN 5 years ago (Oct 15, 2021) would be worth about $251 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $18,305.
CLNN trailed the S&P 500 in all 6 periods.
| Period | CLNN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CLNN: down 19.7% S&P 500: up 1.2% | CLNN trailed the S&P 500 by 20.9 percentage points Trailed |
| 3M | CLNN: down 45.5% S&P 500: up 1.7% | CLNN trailed the S&P 500 by 47.2 percentage points Trailed |
| YTD | CLNN: down 47.2% S&P 500: up 11.9% | CLNN trailed the S&P 500 by 59.1 percentage points Trailed |
| 1Y | CLNN: down 62.4% S&P 500: up 15.5% | CLNN trailed the S&P 500 by 77.9 percentage points Trailed |
| Long term | ||
| 3Y | CLNN: down 70.2% S&P 500: up 75.0% −33.2% vs +20.5% a year | CLNN trailed the S&P 500 by 145.2 percentage points Trailed |
| 5Y | CLNN: down 97.5% S&P 500: up 71.2% −52.1% vs +11.4% a year | CLNN trailed the S&P 500 by 168.7 percentage points Trailed |
$10,000 invested in CLNN 5 years ago (Oct 15, 2021) would be worth about $251 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $17,118.
All-time high
$326.00
Closing high on . Now 99.0% below that record.
Split-adjusted daily closes since Dec 31, 2020.
Stock splits
1
1-for-20 on . Share counts adjust after each split.
Valuation
Financials
About Clene Inc
Clene Inc., (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland.
- Sector
- Industry
- Headquarters
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
CLNN news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CLNN stock FAQ
What is CLNN stock’s price today?
Clene (CLNN) traded at $3.10 at the close on , down $0.21 (6.20%) from the previous close of $3.31. Over the past 52 weeks it has traded between $3.02 and $13.50.
If you invested $1,000 in CLNN 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CLNN on would be worth about $25 at the close on , a total return of −97.5%. The same $1,000 would be worth $376 if invested one year ago. Past performance doesn’t predict future returns.
Does CLNN pay a dividend?
Clene hasn’t paid a dividend in the last twelve months.
What is CLNN’s 52-week high and low?
Over the past 52 weeks CLNN has traded as low as $3.02 and as high as $13.50. At $3.10 at the close on , it is 77.0% below that high and 2.8% above the low.
What is CLNN’s all-time high?
CLNN’s highest closing price was $326.00 on , adjusted for stock splits. At $3.10 at the close on , it is 99.0% below that record.
Has CLNN stock ever split?
Yes, once: 1-for-20 on .
How has CLNN stock performed?
Including dividends and measured to the close on , CLNN has returned −47.2% so far this year and −62.4% over the past year, and −97.5% over five years (−52.1% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What exchange does CLNN trade on?
Clene trades on the Nasdaq under the ticker symbol CLNN. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.